Morgens Waterfall Vintiadis & Co’s TherapeuticsMD TXMD Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-5,000	Closed	-$605K	–	51
2019 Q4	$605K	Buy	5,000 +2,760	+123%	+$397K	0.41%	42
2019 Q3	$407K	Hold	2,240	–	–	0.31%	49
2019 Q2	$291K	Hold	2,240	–	–	0.2%	54
2019 Q1	$545K	Hold	2,240	–	–	0.39%	49
2018 Q4	$427K	Hold	2,240	–	–	0.38%	53
2018 Q3	$735K	Hold	2,240	–	–	0.48%	46
2018 Q2	$699K	Hold	2,240	–	–	0.5%	40
2018 Q1	$545K	Hold	2,240	–	–	0.41%	46
2017 Q4	$676K	Hold	2,240	–	–	0.53%	35
2017 Q3	$592K	Buy	+2,240	New	+$648K	0.5%	39
2017 Q2	–	Sell	-3,600	Closed	-$1.3M	–	65
2017 Q1	$1.3M	Hold	3,600	–	–	1.15%	37
2016 Q4	$1.04M	Hold	3,600	–	–	0.99%	34
2016 Q3	$1.23M	Hold	3,600	–	–	1.07%	37
2016 Q2	$1.53M	Hold	3,600	–	–	1.41%	28
2016 Q1	$1.15M	Hold	3,600	–	–	0.8%	44
2015 Q4	$1.87M	Hold	3,600	–	–	0.78%	26
2015 Q3	$1.05M	Hold	3,600	–	–	0.58%	37
2015 Q2	$1.42M	Sell	3,600 -2,000	-36%	-$706K	0.89%	40
2015 Q1	$1.69M	Buy	+5,600	New	+$1.37M	1.09%	29

Other funds holding TXMD

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's TXMD Position: Q1 2020 in Review

Morgens Waterfall Vintiadis & Co sold out of TherapeuticsMD (TXMD) in Q1 2020, closing a stake of 5,000 shares — an estimated $605K sold.

Morgens Waterfall Vintiadis & Co first reported a position in TXMD in Q1 2015 and held it in 19 quarters. The position peaked at $1.87M in Q4 2015. 143 funds tracked by Wall St. Rank hold TXMD as of Q1 2020.

Morgens Waterfall Vintiadis & Co reported no remaining TherapeuticsMD position as of Q1 2020 after selling out during the quarter.
Morgens Waterfall Vintiadis & Co sold 5,000 TherapeuticsMD shares in Q1 2020, an estimated $605K.
Morgens Waterfall Vintiadis & Co first reported a position in TherapeuticsMD in Q1 2015 and held it in 19 quarters.
Morgens Waterfall Vintiadis & Co's TherapeuticsMD position peaked at $1.87M in Q4 2015.
143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2020.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q1 2020, filed 15 May 2020.